A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 7, 1996, Pages 763-766

  Annoura, Hirokazu ^a   Fukunaga, Atsuko ^a   Uesugi, Mayumi ^a   Tatsuoka, Toshio ^a   Horikawa, Yoshiko ^a  

^a SUNTORY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 (HYDROXYIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXYLIC ACID DERIVATIVE; ALPHA METHYL 4 CARBOXYPHENYLGLYCINE; CHROMENE DERIVATIVE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; METABOTROPIC RECEPTOR; PHOSPHOLIPASE C; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; CALCIUM MOBILIZATION; CHO CELL; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FROG; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OOCYTE; RAT; REACTION ANALYSIS;

ANIMALIA; ANURA;

EID: 0029876140     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00104-7     Document Type: Article

References (30)

1. For reviews: (a) Schoepp, D.; Bockaert, J.; Sladeczek, F.; Trends Pharmacol. Sci. 1990, 11, 1508;
2. (b) Nakanishi, S.; Science 1992, 258, 597;
3. c) Schoepp, D. D.; Conn, P. J.; Trends Pharmacol. Sci. 1993, 14, 13;
4. d) Nakanishi, S.; Neuron 1994, 13, 1031;
5. (e) Hollmann, M.; Heinemann, S.; Annu. Rev. Neurosci. 1994, 17, 31;
6. (f) Watkins, J.; Collingridge, G.; Trends Pharmacol. Sci. 1994, 15, 333;
7. (g) Knopfel, T.; Kuhn, R.; Allgeier, H.; J. Med. Chem. 1995, 38, 1417.
8. (a) Masu, M.; Tanabe, Y.; Tsuchida, K.; Shigemoto, R.; Nakanishi, S.; Nature 1991, 349, 760;
9. (b) Tanabe, Y.; Masu, M.; Ishi, T.; Sigemoto, R.; Nakanishi, S.; Neuron 1992, 8, 169;
10. c) Aramori, I.; Nakanishi, S.; Neuron 1992, 8, 757;
11. d) Abe, T.; Sugihara, H.; Nawa, H.; Shigemoto, R.; Mizuno, N.; Nakanishi, S.; J. Biol. Chem. 1992, 267, 13361.
12. (a) Palmer, E.; Monaghan, D. T.; Cotman, C. W.; Eur. J. Pharmacol. 1989, 166, 585;
13. (b) Irving, A. J.; Schofield, J. G.; Watkins, J. C.; Sunter, D. C.; Collingridge, G. L.; ibid. 1990, 186, 363;
14. c) Nakagawa, Y.; Saito, K.; Ishihara, T.; Ishida, M.; Shinozaki, H.; ibid. 1990, 184, 205;
15. d) Ishida, M.; Akagi, H.; Shimamoto, K.; Ohfune, Y.; Shinozaki, H.; Brain Res. 1990, 537, 311;
16. (e) Ishida, M.; Saitoh, T.; Shimamoto, K.; Ohfune, Y.; Shinozaki, H.; Br. J. Pharmacol. 1993, 109, 1169;
17. (f) Ishida, M.; Saitoh, T.; Shinozaki, H.; Neurosci. Lett. 1993, 160, 156;
18. (g) Hayashi, Y.; Sekiyama, N.; Nakanishi, S.; Jane, D. E.; Sunter, D. C.; Birse, E. F.; Udvarhelyi, P. M.; Watkins, J. C.; J. Neurosci. 1994, 14, 3370.
19. After we presented this study at AFMC International Medicinal Chemistry Symposium in Tokyo, September 3-8, 1995 (abstract p.79), Pellicciari et al. reported that 1-aminoindan-1,5-dicarboxylic acid, a confomationally constrained 2-(carboxyphenyl)glycine analogue, is a potent antagonist for mGluR1: Pellicciari, R.; Luneia, R.; Costantino, G.; Marinozzi, M.; Natalini, B.; Moroni, F.; Thomsen, C.; J. Med. Chem. 1995, 38, 3717.
20. After we presented this study at AFMC International Medicinal Chemistry Symposium in Tokyo, September 3-8, 1995 (abstract p.79), Pellicciari et al. reported that 1-aminoindan-1,5-dicarboxylic acid, a confomationally constrained 2-(carboxyphenyl)glycine analogue, is a potent antagonist for mGluR1: Pellicciari, R.; Luneia, R.; Costantino, G.; Marinozzi, M.; Natalini, B.; Moroni, F.; Thomsen, C.; J. Med. Chem. 1995, 38, 3717.
21. (a) Dean, F. M.; Johnson, R. S.; J. Chem. Soc. Perkin Trans. 1 1981, 224;
22. (b) Dicker, I. D.; Shipman, J.; Suschitzky, J. L.; ibid. 1984, 487.
23. Corey, E. J.; Chaykovsky, M.; J. Am. Chem. Soc. 1965, 87, 1353.
24. Prepared from commercially available 4-oxo-4H-benzopyran-2-carboxylic acid: (a) Ellis, G.P.; Becket, G. J. P.; Shaw, D.; Wilson, H. K.; Vardey, C. J.; Skidmore, I. F.; J. Med. Chem. 1978, 27, 1120;
25. (b) Davidson, D. N.; Kaye, P. T.; J. Chem. Soc. Perkin Trans. 2 1991, 927.
26. 5b (Matrix Presented)
27. 1H-NMR (270 MHz, CDCl3) δ: 1.35 (3H, t, J=7.26 Hz), 1.49 (1H, m), 2.05, (1H, dd, J=10.56 and 5.95 Hz), 3.38 (1H, dd, J=10.56 and 7.26 Hz), 4.28 (2H, q, J=7.26 Hz), 6.98 (1H, d, J=7.92Hz), 7.03 (1H, d, J=8.58 Hz), 7.32 (1H, m), 7.51 (1H, s, OH, exchangeable with D2O), 7.74 (1H, dd, J=7.92 and 1.32 Hz).
28. 1H-NMR (270 MHz, CDCl3) δ: 1.35 (3H, t, J=7.26 Hz), 1.49 (1H, m), 1.84, (1H, dd, J=10.56 and 5.95 Hz), 2.85 (1H, dd, J=10.56 and 7.26 Hz), 4.32 (2H, q, J=7.26 Hz), 7.04 (1H, d, J=7.92Hz), 7.09 (1H, d, J=8.58 Hz), 7.37 (1H, m), 8.44 (1H, dd, J=7.92 and 1.32 Hz), 8.92 (1H, brs, OH, exchangeable with D2O).
29. (S)-4CPG (3a) acts not only as an antagonist at mGluR1 but also as a week agonist at mGluR2. (RS)-MCPG (3b) is a nonselective antagonist for mGluR1 and mGluR2: See ref. If, 3g.
30. Sugiyama, Y.; Ito, I.; Hirono, C.; Nature 1987, 325, 531.